can tirzepatide cause birth defects and Pregnancy: Safety Facts Tirzepatide Use During Pregnancy

| 07.15.26 | 12 min read

Why glucagon activation drives liver fat reduction This is not a coincidence

Proton pump inhibitors and risk of incident CKD and progression to ESRD

Long-term glucagon-like peptide-1 receptor agonist use is not associated with increased risk of thyroid cancer in adults with type 2 diabetes

When administered subcutaneously once weekly, tirzepatide enhances glucose-dependent insulin secretion from pancreatic beta cells, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying

Beginners start at 5 mg once weekly for 2 weeks to assess tolerance, then can increase to 5 mg twice weekly (10 mg/week total) for performance goals